MolecularHealth is a leading provider of molecular cancer analytics and interpretation to improve the life of cancer patients. We use next generation sequencing (NGS) for detection of DNA alterations to determine efficacy and safety of cancer drugs, in combination with advanced information technologies such as text data mining and our proprietary cancer knowledge base for data analyses and interpretation for the comprehensive priorization of treatment options.
Molecular Health GmbH has developed the TreatmentMAP-engine, a software platform which has been certified, according to ISO 13485 and registered as medical device in Europe. We work together with leading certified partners in NGS and in partnership with some of the world's leading healthcare and information technology companies which include the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). MolecularHealth's global headquarter is located in Heidelberg/Germany – the European hotspot for biomedical cancer research. US-operations are headquartered in The Woodlands/Texas were the company has a CLIA-certified NGS lab.
